AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Rhythm Pharmaceuticals COO Pamela Cramer Sells 1520 Shares at $85.93 Each on 2025-07-29.
ByAinvest
Tuesday, Jul 29, 2025 7:00 pm ET1min read
Rhythm Pharmaceuticals, Inc. (RYTM) announced that Chief Human Resources Officer Pamela J. Cramer has sold 1,520 shares at $85.93 per share on July 29, 2025.
Rhythm Pharmaceuticals, Inc. (RYTM), a biopharmaceutical company, reported that its Chief Human Resources Officer, Pamela J. Cramer, sold 1,520 shares of the company's common stock on July 29, 2025. The sale was executed at $85.93 per share [2].The transaction occurred amidst a period of market anticipation surrounding Rhythm Pharmaceuticals' upcoming earnings report, scheduled for release on August 5, 2025. Wall Street analysts expect the company to report a year-over-year decline in earnings, despite a significant increase in revenue [1].
The sale by Cramer, who holds a 10% ownership stake in the company, comes as analysts have recently revised their earnings estimates downward. The consensus estimate now projects a quarterly loss of $0.66 per share, representing a 20% year-over-year decrease. Revenue is expected to rise by 49.3% to $43.41 million [1].
The Earnings ESP (Expected Surprise Prediction) model, developed by Zacks Investment Research, indicates a negative ESP of -9.85% for Rhythm Pharmaceuticals. This suggests that analysts have become more bearish on the company's earnings prospects. The Zacks Rank of #3 for the stock makes it difficult to predict an earnings beat, although the company has a history of beating estimates in the past [1].
Investors should monitor the upcoming earnings report and other factors influencing the stock's performance. While the sale by Cramer may indicate a shift in sentiment, it is essential to consider the broader market conditions and the company's earnings trajectory.
References:
[1] https://www.nasdaq.com/articles/earnings-preview-rhythm-pharmaceuticals-inc-rytm-q2-earnings-expected-decline
[2] https://www.streetinsider.com/SEC+Filings/Form+4+RHYTHM+PHARMACEUTICALS%2C+For%3A+Jul+26+Filed+by%3A+Cramer+Pamela+J./25116049.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet